• This is the free base form of erlotinib; please see our product Erlotinib, Hydrochloride Salt, Cat. No. E-4007, for further technical information. The hydrochloride salt form of erlotinib, not the free base, is used in the erlotinib formulation for use in humans.
• Erlotinib (as the hydrochloride salt) is the active ingredient in the drug product sold under the trade name Tarceva®. This drug has been approved in at least one country for use in patients with pancreatic cancer, non-small cell lung cancer and several other types of cancer. NOTE: THE ERLOTINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT TARCEVA®, AND IS NOT FOR HUMAN USE.
• This erlotinib product is the free base, whose CAS number is given above. The CAS number of the hydrochloride salt is 183319-69-9.
• Related CAS numbers: 248594-19-6 for erlotinib mesylate.
• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.

Related Terms:

Storage

Solubility

Disposal